Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2

IL-2

Brief Information

Name:Interleukin-2
Target Synonym:T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IL2-H4113-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2, Tag Free (Cat. No. IL2-H4113) stimulates proliferation of CTLL-2 cells. The ED50 for this effect is 0.284-0.355 ng/ml (Routinely tested).

IL2-H4113-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

IL2-H52H8-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human IL-2RB&IL-2RA&IL-2RG, Fc,Avitag&Fc,Avitag (Cat. No. ILG-H82F4) on SA Biosensor, can bind Human IL-2, His Tag (Cat. No. IL2-H52H8) with an affinity constant of 2.41 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

IL2,TCGF,lymphokine,Interleukin 2

Background

Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SHR-1916 SHR-1916 Phase 1 Clinical Solid tumours Details
HBAI-20 HBAI-20; HBAI-20-CyTuVax Phase 2 Clinical Cytuvax Hepatitis B Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Atherosclerosis; Carcinoma, Basal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Carcinoma, Squamous Cell; Melanoma Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St. Jude Children'S Research Hospital, National Cancer Institute Neuroblastoma Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
S-95007 S-95007 Phase 2 Clinical Servier Immune System Diseases; Inflammation Details
Autologous tumor cell vaccine (NCI) Phase 2 Clinical H Lee Moffitt Cancer Center & Research Institute, National Cancer Institute, Chiron Spa Carcinoma, Renal Cell; Melanoma Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
ITI-1000 ITI-1000 Phase 2 Clinical Immunomic Therapeutics Glioblastoma Details
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) Phase 2 Clinical Tcrcure Biopharma Ltd Nasopharyngeal Carcinoma Details
mRNA-6231 mRNA-6231 Phase 1 Clinical Autoimmune Diseases Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
XTX-202 XTX-202 Phase 2 Clinical Solid tumours Details
STK-012 STK-012 Phase 1 Clinical Synthekine Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Microsatellite instability-high cancer; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Melanoma Details
PM-1016 PM1016; TILT-123 Phase 2 Clinical Tilt Biotherapeutics Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Melanoma Details
NNC-0361-0041 NNC0361-0041; NNC-0361-0041 Phase 1 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1 Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message